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ABSTRACT Lassa virus (LASV) infection is a major public health concern due to high fatality rates and limited effective treat-
ment. The interferon-stimulated gene cholesterol 25-hydroxylase (CH25H) encodes an enzyme that catalyzes the production of
25-hydroxycholesterol (25HC). 25HC is involved in regulating cholesterol biosynthesis and has recently been identified as a po-
tent antiviral targeting enveloped virus entry. Here, we show a previously unrecognized role of CH25H in inhibiting LASV glyco-
protein glycosylation and the production of infectious virus. Overexpression of CH25H or treatment with 25HC decreased LASV
G1 glycoprotein N-glycan maturation and reduced the production of infectious LASV. Depletion of endogenous CH25H using
small interfering RNA (siRNA) enhanced the levels of fully glycosylated G1 and increased infectious LASV production. Finally,
LASV particles produced from 25HC-treated cells were found to be less infectious, to incorporate aberrantly glycosylated GP1
species, and to be defective in binding alpha-dystroglycan, an attachment and entry receptor. Our findings identify a novel role
for CH25H in controlling LASV propagation and indicate that manipulation of the expression of CH25H or the administration
of 25HC may be a useful anti-LASV therapy.
IMPORTANCE Lassa fever is an acute viral hemorrhagic fever in humans caused by Lassa virus (LASV). No vaccine for LASV is
currently available. Treatment is limited to the administration of ribavirin, which is only effective when given early in the course
of illness. Cholesterol 25-hydroxylase (CH25H) is a recently identified interferon-stimulated gene (ISG); it encodes an enzyme
that catalyzes the production of 25-hydroxycholesterol (25HC), which inhibits several viruses. Here, we identify a novel antiviral
mechanism of 25HC that is dependent on inhibiting the glycosylation of Lassa virus (LASV) glycoprotein and reducing the infec-
tivity of LASV as a means of suppressing viral replication. Since N-linked glycosylation is a critical feature of other enveloped-
virus glycoproteins, 25HC may be a broad inhibitor of virus infectivity.
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Arenaviridae is a family of enveloped, negative-strand RNA vi-ruses that can cause severe disease in humans; it includes Lassa
virus (LASV), lymphocytic choriomeningitis virus (LCMV), Lujo
virus, Junin virus, and Machupo virus. LASV, the most prevalent
cause of arenavirus infection, is endemic to West Africa and causes
an estimated 300,000 infections annually, with case fatality rates as
high as 20% (1, 2). LASV is classified as a biosafety level 4 (BSL-4)
and NIAID biodefense category A agent (1). Patients infected with
LASV have initial nonspecific symptoms similar to those of Ebola
virus infection, including fever, headaches, muscle pain, weak-
ness, fatigue, and vomiting. In severe cases, LASV disease can be
associated with a bleeding diathesis; death occurs due to multior-
gan failure (2, 3). No vaccine for LASV is currently approved, and
ribavirin, the sole available drug, is only effective if administered
early in infection (2, 4). The death of a patient with Lassa fever in
the United States in 2015 (5) demonstrates that even excellent
intensive care cannot always prevent a fatal outcome and empha-
sizes the need for developing effective vaccines and novel thera-
pies.
The LASV genome consists of 2 single-stranded ambisense
RNA segments, one large (L; 7.2 kb) and one small (S; 3.4 kb).
L encodes the viral polymerase and the zinc-binding protein (Z
or matrix protein). S encodes the nucleoprotein (NP) and gly-
coprotein precursor (GPC). The LASV GPC, synthesized as a
single protein, is cleaved posttranslationally into GP1 and GP2
by the cellular enzyme site 1 protease SKI-1/S1P (6, 7). These
subunits oligomerize, forming spikes on the surface of the vi-
rion. GP1 is responsible for virus attachment to host cell recep-
tors, while GP2 mediates fusion of the viral and endosomal
membranes (8, 9). GPC must be glycosylated for correct fold-
ing in order to be cleaved by SKI-1/S1P (10). In addition, gly-
cosylation of GP1/GP2 is needed for their transport to sites of
viral budding, as well as for LASV antigenicity and infectivity
(6, 11, 12). Hence, the processes of LASV GPC cleavage, glyco-
sylation, and maturation represent targets for potential antivi-
ral strategies.
Cholesterol 25-hydroxylase (CH25H) is a newly identified, con-
served interferon-stimulated gene (ISG) that encodes an enzyme
that catalyzes the oxidation of cholesterol into 25-hydroxy-
cholesterol (25HC) (13). The antiviral effects of CH25H have
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been predominantly attributed to its enzymatic activity through
the production of 25HC, which has been shown to block infection
by several enveloped viruses (14–17). The antiviral function of
25HC involves multiple mechanisms, including blocking fusion
of the viral envelope with host membranes (14), inhibiting viral
replication (14, 15), and inhibiting the formation of viral replica-
tion complexes on intracellular membranes (17). 25HC was also
reported to inhibit a postentry step of viral infection by repressing
the activation of SREBP (16), a transcription factor required for
lipid and cholesterol biosynthesis. More recently, 25HC has also
been shown to block the replication of nonenveloped viruses (18).
These findings demonstrate that 25HC has broad-spectrum anti-
viral effects. Understanding the mechanisms by which 25HC ex-
erts antiviral activity may help to identify strategies and targets for
potential intervention.
Here, we report that 25HC restricted LASV infection by induc-
ing the biosynthesis of an aberrantly glycosylated form of GP1,
which was efficiently incorporated into LASV particles. Incorpo-
ration of the aberrantly glycosylated GP1 was accompanied by
reduced LASV infectivity and binding to alpha-dystroglycan
(alpha-DG), a cell surface protein involved in LASV attachment
and endocytosis (19, 20). Our findings suggest that 25HC can
restrict virus infection by a previously unrecognized mechanism
linking improper glycosylation and binding of the viral glycopro-
tein to a cellular receptor.
RESULTS
25HC impairs LASV production. We first tested the ability of
25HC to reduce the production of infectious LASV. Huh7 cells
were treated for 1 h with either ethanol (vehicle control) or 5 or
10 M of 25HC and then infected with LASV at a multiplicity of
infection (MOI) of 0.1. The LASV titers were reduced by both
concentrations of 25HC at 48 and 72 h postinfection (hpi). At
5 M, 25HC inhibited the production of infectious LASV titers by
1.1 log, and 10 M of 25HC inhibited LASV titers by 1.4 log
(Fig. 1A). These decreases in viral titers were not due to cellular
toxicity, as no significant cytotoxic effects were measured over the
same time period (Fig. 1B).
LASV infectivity is reduced by 25HC treatment. Next, we
used quantitative reverse transcription-PCR (qRT-PCR) to deter-
mine LASV RNA copy numbers in supernatants of LASV-infected
cells. In contrast to LASV infectious titers (Fig. 1A), the extracel-
lular LASV RNA levels from control and 25HC-treated samples
increased to 1  109 copies per ml at 72 hpi, and 25HC treatment
did not affect viral RNA release (Fig. 1C). To highlight the differ-
ences between LASV titers and viral RNA copy numbers due to
25HC treatment, we calculated the ratio of infectious LASV (50%
tissue culture infective dose [TCID50]/ml) to viral RNA copy
number (Fig. 1D). In 25HC-treated cells, the ratio was reduced to
~15% of the values for controls at 48 and 72 hpi, suggesting that
the loss in LASV infectivity was most notable after 24 hpi.
FIG 1 25-Hydroxycholesterol inhibits infectious Lassa virus production. (A) Culture supernatants of cells infected with Lassa virus (LASV; MOI of 0.1)
pretreated with ethanol (EtOH; vehicle control) or indicated concentrations of 25-hydroxycholesterol (25HC) were harvested at different times postinfection
(hours postinfection [hpi]), and viral titers were quantified by 50% tissue culture infective dose (TCID50) assay. (B) Cell viabilities (%) of 25HC-treated and
mock-infected cells were determined after 72 h of treatment. Values were normalized to those of ethanol controls. (C) RNA was extracted from supernatants of
cells infected as described for panel A. Absolute quantification of viral RNA copy numbers was done using a standard curve with known viral titers. Mean RNA
copy numbers are shown, with error bars indicating standard deviations calculated from the results of 3 independent experiments. (D) Ratios were calculated
using TCID50/ml values from the experiment whose results are shown in panel A divided by the extracellular viral RNA copy numbers from the experiment whose
results are shown in panel B. Mean specific infectivity was calculated as the percentage of the mean value for ethanol-treated samples at 72 hpi, with error bars
indicating standard deviations calculated from the results of 3 independent experiments.
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Previous reports suggest that 25HC blocks cell entry of envel-
oped viruses (14). To assess whether the impaired LASV infectiv-
ity was due to inhibited LASV entry, we measured the levels of
cell-associated LASV S genome at an early time point after infec-
tion. Huh7 cells pretreated with 25HC were infected with LASV at
an MOI of 1. S segment RNA levels were measured by qRT-PCR
and normalized to the level of glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) mRNA. As shown by the results in Fig. S1 in
the supplemental material, the S genome levels did not differ sig-
nificantly among the samples, indicating that 25HC did not affect
the levels of internalized LASV genome. On the other hand, treat-
ment with the positive-control BIBX 1382, previously shown to
inhibit LASV glycoprotein-dependent entry (21), significantly re-
duced the S genome levels. These results are consistent with 25HC
not affecting the initial stages of LASV entry.
25HC alters the electrophoretic mobility of glycosylated
GP1. To understand the mechanism by which 25HC reduces
LASV infectivity, we examined the viral proteins in the lysates of
LASV-infected cells. Western blot analysis using a monoclonal
antibody (MAb) recognizing the GP1 region detected GPC mi-
grating at ~75 kDa and the cleavage product GP1 as a diffuse 40- to
42-kDa band in lysates of untreated cells (Fig. 2A). At 48 h, treat-
ment with 5 and 10 M 25HC decreased the levels of the 42-kDa
species but not the 75-kDa species. At 72 hpi, the intensity of the
42-kDa band shifted below ~40 kDa. 25HC treatment also
changed the GPC levels (Fig. 2A, lane 7 versus lane 9), but the ratio
of GP1 cleavage efficiency [%GP1/(GP1  GPC)] was unaffected.
25HC treatment caused decreased LASV NP levels at 24 and
48 hpi, but the NP levels were similar to those in the vehicle con-
trol at 72 hpi. Thus, 25HC increased GP1 mobility on SDS-PAGE
gels and reduced infectious LASV production (Fig. 2A and 1A).
25HC inhibits LASV GP1 glycosylation in LASV GPC-
transfected cells. Cleavage of LASV GPC by SKI-1/S1P is essential
for the production of infectious virus. The reduced LASV titers in
25HC-treated cells (Fig. 1A) could be due to reduced cleavage or
reduced glycosylation of LASV GPC. Thus, we next looked at
the expression of GPC and GP1 in Huh7 cells transfected with
LASV GPC and treated with 25HC or ethanol vehicle control.
Cells were treated with 25HC, and cell lysates were analyzed
by Western blotting with antibodies for GP1 or actin. GPC-
transfected and ethanol-treated cells showed GPC and GP1 elec-
trophoretic mobilities similar to those of the LASV-infected cells
(compare Fig. 2B and A), with the precursor protein migrating at
~75 kDa and the majority of GP1 detected at ~40 to 42 kDa. After
24 h of treatment, 25HC did not have a significant effect on GP1
glycosylation in GPC-transfected cells (see Fig. S2 in the supple-
mental material). However, after 48 h, similar to the results for
LASV-infected cells, 5 M or 10 M of 25HC resulted in a distinct
shift in GP1 mobility on SDS-PAGE gels, from ~40 to 42 kDa to
below ~40 kDa. The unprocessed GPC band shifted also, from
~75 kDa to ~73 kDa, after 25HC treatment. Although the overall
levels of GPC and GP1 appeared slightly reduced upon 25HC
treatment, 25HC did not affect GPC cleavage efficiency, as dem-
onstrated by quantifying GP1 and GPC levels in cell lysates
(Fig. 2B). No effect on the level or the migration of the endoge-
nous protein mannose 6-phosphate receptor (M6PR), which con-
tains 5 potential N-linked glycosylation sites (22), was detected by
25HC treatment. Thus, 25HC specifically increased GP1 mobility
on SDS-PAGE gels but did not affect GPC cleavage efficiency in
the absence of other viral proteins.
To test whether the change in GP1 mobility on SDS-PAGE gels
was due to changes in glycosylation, the lysates of cells transfected
with LASV GPC were treated with endoglycosidase H (Endo-H)
or peptide-N-glycosidase F (PNGase F). Treatment with PNGase
F, which removes all N-linked glycans, caused the majority of GP1
to migrate at between ~20 and ~24 kDa (instead of ~40 to 42); this
pattern was observed regardless of whether 25HC was used
(Fig. 2C, lanes 3, 6, and 9). Without 25HC, Endo-H digestion,
which removes high-mannose species while leaving the most
complex and hybrid glycans intact, resulted in a shift of intensity
of the ~40- to 42-kDa GP1 band to just below ~40 kDa in the
lysates of control cells (Fig. 2C, lane 1 versus lane 2). In contrast,
when 25HC-treated lysates were digested with Endo-H, the inten-
sity of the GP1 species migrating below ~40 kDa was decreased,
and multiple additional GP1 bands migrating from ~40 kDa to
~22 kDa became apparent (Fig. 2C, lanes 2, 5, and 8, top). To-
gether, this indicated that the GP1 species below ~40 kDa are
more sensitive to Endo-H digestion in 25HC-treated lysates than
in lysates of control cells; this increase in sensitivity suggests that
the maturation of GP1 N-glycans was impaired by 25HC. In con-
trast, GP2 sensitivity to Endo-H digestion was minimally affected
in the presence and absence of 25HC (Fig. 2C lanes 2, 5, and 8,
bottom). Taken together, these results indicate that 25HC treat-
ment leads to the production of aberrantly glycosylated forms of
GP1 that contain more immature N-glycans.
Overexpression of CH25H alters GP1 electrophoretic mobil-
ity and LASV production. 25HC is generated by the enzyme
CH25H. To confirm a role for CH25H in GPC glycosylation, we
overexpressed this enzyme in Huh7 cells. Huh7 cells transfected
with Myc-tagged CH25H or with empty plasmid were transfected
with LASV GPC, and GP1 expression was analyzed by Western
blotting. As a negative control, we used Myc-tagged IFITM3, an-
other ISG that can block virus entry by disrupting intracellular
cholesterol homeostasis (23, 24). The expression of CH25H and
IFITM3 was confirmed by Western blotting (Fig. 3A). As seen
with 25HC treatment, CH25H transfection altered the migration
of GP1 to below 40 kDa (Fig. 3A). In contrast, no shift in GP1 band
intensity was observed in cells transfected with either empty plas-
mid or IFITM3.
To investigate whether the expression of CH25H also affected
GP1 glycosylation during LASV infection, as it does in GPC-
transfected cells, we overexpressed CH25H in Huh7 cells and in-
fected these cells with LASV. The expression of CH25H, but not of
IFITM3, shifted the GP1 band at 72 hpi (Fig. 3B), similar to 25HC
treatment (Fig. 2A). Furthermore, cells overexpressing CH25H
produced 5 times less LASV than infected cells that received the
empty vector (Fig. 3C). In comparison, IFITM3 overexpression
did not affect LASV growth (Fig. 3C). Thus, CH25H overexpres-
sion altered LASV GP1 glycosylation and decreased LASV produc-
tion. Taken together, the similar effects of CH25H expression and
25HC treatment suggest that 25HC synthesized by CH25H is re-
sponsible for the effects of CH25H transfection.
Knocking down CH25H expression increases LASV produc-
tion. To evaluate the role of endogenous CH25H in LASV GP1
glycosylation and the reduction of LASV titers, we silenced
CH25H mRNA expression under sterol-depleted conditions. Ste-
rol depletion was used to increase CH25H expression to help de-
tect changes in GP1 glycosylation and LASV titers. In LASV-
infected cells, small interfering RNA (siRNA) targeting CH25H
reduced its expression by more than 85% (Fig. 3D), and no change
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in CH25H levels was observed in control cells treated with siRNA
targeting IFITM3 or scrambled siRNA. Cells treated with CH25H
siRNA showed increased intensity in the GP1 band at 42 kDa,
consistent with more complex N-glycan content in GP1 (Fig. 3E).
Increased intensity of the 42-kDa GP1 band was also accompanied
by an ~fourfold increase in LASV titers compared to the titers in
cells transfected with control or IFITM3 siRNA (Fig. 3F). No
change in NP levels was detected in cells transfected with CH25H
siRNA. These results suggested that knocking down CH25H in-
creased the yield of the 42-kDa GP1 species and enhanced LASV
replication.
Aberrantly glycosylated GP1 incorporates into virions. A
possible cause for reduced LASV infectivity in 25HC-treated cells
may be the incorporation of aberrantly glycosylated GP1 into
LASV particles. To determine whether virus particles released
from 25HC-treated cells contain aberrantly glycosylated GP1, su-
pernatants of control or 25HC-treated cells were sedimented
through a 20% sucrose cushion. No uncleaved GPC (~75 kDa)
FIG 2 25HC treatment affects LASV GP1 glycosylation. (A) Huh7 cells were infected with LASV and treated with ethanol or 25HC as described in the legend
to Fig. 1A. Cell lysates were harvested at different times after infection, and GP1 and actin expression levels were determined by Western blotting. ns, nonspecific
binding. (B) Huh7 cells were transfected with a plasmid expressing LASV GPC and treated with 25HC. The levels of GP1 and actin expression in cell lysates were
then analyzed by Western blotting. To determine the extent of GPC cleavage, blot images were subjected to densitometry analysis. Percentage of GP1 was
determined by dividing the GP1 signal by the total amount of glycoprotein recognized by GP1 MAb (GP1/GPC  GP1). (C) Cell lysates prepared from 25HC
treated and LASV-GPC transfected cells as described for panel B were either left untreated or were digested with Endo-H or PNGase. The levels of GP1, GP2, and
actin expression were then visualized by Western blotting.
Shrivastava-Ranjan et al.
4 ® mbio.asm.org November/December 2016 Volume 7 Issue 6 e01808-16
was detected in the pelleted virions (Fig. 4A, left versus right), as
previously reported (6). The NP levels were comparable in all
samples. Virus released from control cells contained only the typ-
ically glycosylated form of GP1, migrating between 40 and 42 kDa.
In contrast, in cells treated with 25HC, the majority of GP1 pres-
ent in the pelleted LASV migrated below 40 kDa, indicating that
25HC treatment resulted in efficient incorporation of aberrantly
glycosylated GP1 into LASV particles.
FIG 3 Effects of CH25H overexpression and knockdown on LASV infectivity and GP1. (A) Huh7 cells were transfected with empty vector or plasmid expressing
Myc-tagged cholesterol 25-hydroxylase (CH25H) or Myc-tagged IFITM3. After 24 h, the cells were transfected with LASV GPC. Transfected cells were harvested
48 h later, and GP1 was detected by Western blotting. The membranes were stripped and reprobed, first with anti-Myc antibody and then with antiactin antibody.
ns, nonspecific binding. (B) Huh7 cells transfected with CH25H or IFITM3 were infected with LASV at an MOI of 0.1 24 h posttransfection. Cell lysates and
supernatants were collected at 72 hpi. Western blotting was used to detect GP1, NP, and actin. (C) Huh7 cells were transfected with plasmid expressing CH25H
or IFITM3 and infected with LASV. Cell supernatants were collected at indicated times after infection, and LASV titers were determined by TCID50 assays in
Vero-E6 cells. (D) Huh7 cells were transfected with the indicated siRNAs and then either mock infected or infected with LASV at an MOI of 1.0 in medium
containing 5% lipoprotein-deficient serum. After 24 h, lysates were prepared, and CH25H expression was analyzed by qRT-PCR. CH25H levels were normalized
to levels of GAPDH in each sample. (E) Huh7 cells were transfected with indicated siRNAs and infected with LASV. After 24 h, lysates were collected, and Western
blotting was used to detect GP1, NP, and actin. (F) Huh7 cells were transfected and infected with LASV as described for panel E. After 24 h, supernatants of
infected cells were collected, and LASV titers were determined by TCID50 assays in Vero-E6 cells. *, P  0.05; **, P  0.005.
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LASV virions containing aberrantly glycosylated GP1 are de-
fective in alpha-DG binding. The initial attachment of LASV to
the cell surface is dependent on the host glycoprotein alpha-DG.
To test whether the aberrantly glycosylated LASV particles pro-
duced after 25HC treatment were defective in alpha-DG binding,
we performed a binding assay (20). In this assay, alpha-DG–Fc
fusion proteins were immobilized and incubated with semipuri-
fied LASV preparations obtained from control and 25HC-treated
cells. Equal volumes of purified LASV were incubated on alpha-
DG, and the bound fractions were measured (Fig. 4B). LASV pro-
duced in 25HC-treated cells bound alpha-DG less efficiently than
LASV from control cells, despite the overabundance of GP1 pres-
ent in the particles produced in the presence of 25HC compared to
the amount in particles from control cells (Fig. 4A, lane 3 versus
lanes 1 and 2). These results suggest that binding of the aberrantly
glycosylated form of GP1 to alpha-DG is compromised.
DISCUSSION
Here, we demonstrate that 25HC has antiviral activity against
LASV that is linked to the production of virus particles with re-
duced infectivity. LASV particles produced in the presence of
25HC contained aberrantly glycosylated GP1, the subunit of the
viral glycoprotein responsible for receptor binding. These parti-
cles bound poorly to alpha-DG, the cell surface attachment and
entry factor for LASV. Thus, 25HC inhibits LASV infection by a
novel mechanism that alters the maturation of N-linked glycans,
leading to impaired receptor binding.
The correct folding and cleavage of arenavirus GPC are critical
for the incorporation of GP1 and GP2 into virions, and inhibition
of cleavage results in the release of noninfectious virus particles
devoid of surface glycoproteins (6). 25HC reduced LASV infectiv-
ity, but not through defective GPC cleavage. Instead, 25HC
blocked the maturation of N-linked glycans on the viral glycopro-
tein subunits, rendering them more sensitive to digestion with
Endo-H than the untreated forms; the majority of cell-associated
GPC, GP1, and GP2 glycoproteins were sensitive to Endo-H in
our experiments, but the sensitivity of GP2 to Endo-H was not
affected by 25HC treatment. Although we did not extensively in-
vestigate these apparent differences, the more extensive glycosyl-
ation of GP1 (GP1 has 7 N-glycan sites, versus 4 in GP2) (10)
might facilitate the detection of changes in GP1 glycosylation after
Endo-H treatment, while changes in GP2 are harder to detect.
Since Endo-H only removes immature N-glycans that are rich in
mannose residues, the addition and/or trimming of N-glycans
might be crucial for 25HC-induced reduction of LASV infectivity.
Indeed, abnormal N-glycan maturation due to changing the SKI-/
S1P cleavage motif (RSLK) to a furin motif (RRKR) in Junin virus,
a New World arenavirus, resulted in reduced viral spread, suggest-
ing that glycan maturation might affect arenavirus infectivity in
general (25). The aberrantly glycosylated GP1 was readily incor-
porated into viral particles, though the ability of these particles to
bind alpha-DG was significantly compromised. Although inhibi-
tors of trimming oligomannosyl-rich chains had no effect on the
production of infectious LCMV, another arenavirus that uses
alpha-DG as a receptor (26), the loss of N-glycans in GP1 of
LCMV has been associated with reduction in infectivity (11). Mu-
tating 3 of the 4 N-glycans of LCMV GP1 produces noninfectious
viruslike particles without altering GPC processing, suggesting
that GP1’s glycan composition can be critical for the infectivity of
other arenaviruses (11). Therefore, we propose that the inhibition
of LASV infectivity by 25HC is at least partly due to inefficient
binding of the aberrantly glycosylated GP to alpha-DG.
The mechanism by which 25HC induces changes in the GP1
glycans is currently unknown, but we speculate that Golgi-
complex and trans-Golgi network-associated glycosidases and/or
mannosidases involved in GP1 maturation might be affected by
25HC. Since the conversion of high-mannose oligosaccharide to a
complex type occurs in the medial to trans-Golgi network (27),
our data suggest that LASV GP1 is transported to the cis-Golgi
compartment. This is consistent with our findings that 25HC did
not affect LASV GPC cleavage, a process that occurs in the endo-
plasmic reticulum (ER) and/or cis-Golgi compartment. Accord-
ingly, blocking the complex-N-glycan maturation of HIV glyco-
protein GP120 by inhibiting mannosidase I has been linked to
FIG 4 Differentially glycosylated GP1 species are incorporated into LASV
particles. (A) Cells treated with ethanol or 25HC were infected with LASV at an
MOI of 0.1. Supernatants and cell lysates were collected, and LASV particles
were purified from supernatants by ultracentrifugation through a sucrose
cushion as described in Materials and Methods. Purified LASV particles were
resuspended in 2 sample lysis buffer, and levels of GP1 or NP were analyzed
by Western blotting. ns, nonspecific binding. (B) Alpha-DG–Fc fusion pro-
teins were immobilized on 96-well plates and incubated with semipurified
LASV preparations obtained from control and 25HC-treated cells. Equal vol-
umes of purified LASV were incubated on alpha-DG, and bound fractions
were measured by determining the optical density (OD) at 450 nm. *, P  0.05;
**, P  0.005.
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reduced virion infectivity without changes in GP160 cleavage
(28). Alternatively, a 25HC-induced alteration of normal trans-
port of GPC or its cleaved products might affect the extent of GP1
glycan maturation, although the release of LASV particles follow-
ing 25HC treatment appeared unimpaired.
CH25H is an interferon-stimulated gene, and its expression is
upregulated during infection with hepatitis C and influenza vi-
ruses (16, 29). How LASV infection upregulates CH25H is un-
known, especially since LASV-infected human cells produce
undetectable or very low levels of type-I IFN (30, 31). Further
investigations are required to understand the mechanism of
CH25H transcriptional activation by LASV. CH25H knockdown
enhanced LASV titers and increased the levels of the ~42-kDa GP1
normally found in the virus. LASV containing the ~42-kDa GP1
had better receptor binding activity than LASV bearing the aber-
rantly glycosylated GP1 induced by 25HC. This suggests that the
enhanced LASV titers seen after CH25H knockdown are probably
due to increased LASV infectivity, as CH25H overexpression and
25HC inversely affected both virus titers and glycosylation. How-
ever, further experiments are necessary to rule out the possibility
that CH25H depletion increases the release of viral particles.
While the exact mechanism by which CH25H inhibits GP1
glycosylation remains to be elucidated, our data demonstrate the
importance of CH25H and the unexpected role of GP1 glycosyla-
tion in LASV infectivity. Future experiments are warranted to
more precisely address the biochemical changes of glycans associ-
ated with 25HC treatment and the effect of these changes on
LASV’s interactions with its cell surface receptor.
MATERIALS AND METHODS
Biosafety. All work with infectious virus was conducted in a BSL-4 labo-
ratory at the Centers for Disease Control and Prevention (CDC, Atlanta,
GA), following the guidelines of CDC standard operating procedures.
Cells, virus, plasmids, reagents, and antibodies. Vero-E6 cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM; Life Tech-
nologies, Inc., Grand Island, NY, USA) supplemented with 10% (vol/vol)
fetal calf serum (FCS, HyClone; Thermo Scientific, Waltham, MA, USA)
and penicillin-streptomycin (Life Technologies, Inc.). In some samples,
sterol-depleted medium (lipoprotein-deficient serum; Sigma-Aldrich, St.
Louis, MO, USA) was used instead of medium with FCS. Huh7 cells were
propagated in DMEM with 10% (vol/vol) FCS and 1 nonessential
amino acids (Life Technologies, Inc.). 25HC was from Sigma-Aldrich.
LASV (Josiah strain) was from the CDC Viral Special Pathogens Branch
reference collection; all work with LASV was done under BSL-4 condi-
tions. The plasmid encoding LASV-GPC has been previously described
(21, 32). Plasmids encoding Myc-tagged CH25H and Myc-tagged IFITM3
were purchased from Origene (Rockville, MD, USA). The following anti-
bodies were used in this study: mouse monoclonal antibody against LASV
NP (703079-Lassa Josiah HMAF), mouse monoclonal antibody against
LASV GP1 (52-74-7), monoclonal antibody against LASV GP2 (81001-
52-2085-0006-BG12-alpha-LASVG2), and a mix of 5 monoclonal LASV
antibodies for immunofluorescence (SPR628 anti-LASV 5-MAb mix-
ture). The anti-Myc antibody was from Origene, and the mouse mono-
clonal antiactin antibody was from Sigma-Aldrich (St. Louis, MO, USA).
Transfection and infection. To determine the effects of 25HC on GP1
glycosylation in LASV GPC-transfected cells, Huh7 cells were plated at
2.5  105 per well in 12-well plates. The following day, cells were tran-
siently transfected with 2 g of empty expression vector (pCAGGS) or
with a plasmid expressing LASV-GPC at the indicated concentrations,
using TransIT-LT1 according to the manufacturer’s instructions (Mirus,
Madison, WI, USA). After 24 h, cells were treated with 25HC; cells were
harvested 48 h posttransfection. To determine the effects of CH25H and
IFITM3 overexpression on LASV GPC, Huh7 cells were transfected with
either empty vector (pCMV6) or plasmid expressing Myc-tagged CH25H
or Myc-tagged IFITM3 using TransIT-LT1 (Mirus). After 24 h, cells were
washed twice with DMEM and then retransfected with plasmid expressing
LASV GPC as described above.
For LASV infection, Huh7 cells were plated at 5  105 cells per well in
12-well plates. The next day, cells were treated with ethanol or 25HC in
serum-free medium for 1 h. 25HC treatment was done in serum-free
medium to enhance the effect of the drug by avoiding potential binding of
25HC to serum lipids and proteins. Cells were then infected with LASV at
the indicated MOIs for 1 h. The virus inoculum was removed, and cells
were washed with serum-free medium. Fresh medium containing 2% FCS
and with or without 25HC was then added. To determine the effects of
CH25H or IFITM3 on LASV infection, cells were transfected with either
empty vector (pCMV6) or plasmid expressing Myc-tagged CH25H or
Myc-tagged IFITM3 using TransIT-LT1 (Mirus) as described above. After
24 h, transfected cells were washed twice with DMEM and then infected
with LASV at an MOI of 0.5.
Huh7 cells (2.5  105 per well) were reverse transfected and then
retransfected 48 h later using DharmaFect 1 (Thermo Fisher Scientific)
and 100 nmol siRNA against CH25H or IFITM3 or control siRNA (ON-
Target plus SMARTpool siRNA; Thermo Fisher Scientific). Seventy-
two hours after the initial transfection, cells were infected with LASV at an
MOI of 1 under serum-free conditions. After 1 h of virus adsorption, cells
were washed 4 times with serum-free medium and then replenished with
DMEM containing 5% lipoprotein-deficient serum.
TCID50 determination. Supernatants from LASV-infected cells were
harvested at the indicated time points, and virus titrations were per-
formed in Vero-E6 cells. Three days postinfection, the cells were fixed,
permeabilized, and stained to visualize viral proteins. Endpoint viral titers
were determined, and TCID50s were calculated as described previously
(21). The results represent the mean titers and standard deviations calcu-
lated from the results of 3 independent experiments.
Quantitative RT-PCR. Huh7 cells were infected with LASV for the
indicated times, and then RNA was isolated from cells or from superna-
tants of infected cells using the MagMAX-96 total RNA isolation kit
(Thermo Fisher Scientific). One-step qRT-PCR was performed using an
Applied Biosystems 7500 real-time PCR system and primers specific for
CH25H or IFITM3 from single-tube TaqMan assays (Thermo Fisher Sci-
entific). The levels of target genes were normalized to the GAPDH levels
using control primer-probe sets (Thermo Fisher Scientific). The fold
modulations in gene expression of CH25H and IFITM3 mRNA were an-
alyzed using the cycle threshold (2CT) method, comparing the levels
of target mRNA in LASV-infected cells with the levels in mock-infected
cells. The results shown are the means of CH25H mRNA expression in 3
independent experiments. To determine viral RNA copy numbers, RNA
was extracted from the supernatants of infected cells. Absolute quantifi-
cation of viral RNA copy numbers was done by measuring LASV S seg-
ment copy numbers using a standard curve with known viral titers serially
diluted fivefold. One-step qRT-PCR was conducted using LASV S
segment-specific forward (5=-AATCAGTTCGGGACCATGC-3=) and re-
verse (5=-GTGTTGGGATACTTTGCTGTG-3=) primers and a probe oli-
gonucleotide (5=-/56-FAM/AGTCAACCT/ZEN/GCCCCTGTTTTGTCA
/Iowa Black FQ/-3= [6-FAM is 6-carboxyfluorescein]) from Integrated
DNA Technologies, Inc. (Coralville, IA, USA).
Western blotting. At the indicated times after transfection or infec-
tion, cell lysates were harvested by adding lysis buffer containing 50 mM
NaCl, 5 mM EDTA, 1% NP-40, 0.1% SDS, and 0.5% sodium deoxy-
cholate supplemented with a protease inhibitor cocktail (Sigma-Aldrich).
Lysates from infected cells were gamma irradiated at 2  106 rad using a
high-energy 60Co source. Proteins were electrophoretically separated on
4-to-12% NuPAGE gels (Invitrogen) and transferred to nitrocellulose
membranes. The membranes were blocked for 1 h with buffer containing
Tris-buffered saline, 0.1% Tween 20, and 5% nonfat dry milk and then
probed overnight at 4°C with primary antibodies. The membranes were
developed using horseradish peroxidase-conjugated secondary antibod-
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ies and enhanced chemiluminescence. After the detection of primary an-
tibodies, the membranes were stripped and reprobed with antiactin anti-
body as a loading control. The results shown are representative of 3
independent experiments.
Virion purification. Supernatants from ethanol- or 25HC-treated and
LASV-infected cells were clarified by centrifuging at 1,500  g for 30 min.
Clarified supernatants were subjected to ultracentrifugation (100,000  g
for 90 min at 4°C) through a 20% sucrose cushion to collect LASV virions.
Virions were suspended in 2 Western lysis buffer, gamma irradiated at
5  106 rad using a high-energy 60Co source, and analyzed by Western
blotting to detect GP1 and NP. Alternatively, virions were suspended in
phosphate-buffered saline (PBS) and used for alpha-DG fusion protein
binding enzyme-linked immunosorbent assay (ELISA) under BSL-4 con-
ditions.
Lassa virions and alpha-DG–Fc fusion protein binding ELISA. A
plasmid expressing a fusion protein consisting of the signal sequence
from CD5, the ectodomain of alpha-DG (amino acids 30 to 430), and the
Fc domain of human IgG1 was generated by cloning the alpha-DG se-
quence amplified from RNA extracted from HEK-293 cells into plasmid
pSyngp120IgG (obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH, from Eun-Chung Park
and Brian Seed). The expression and purification of the DG3.5-Fc fusion
protein were performed by GenScript (Piscataway, NJ). Briefly, the ex-
pression plasmid was transiently transfected into a suspension of HEK-
293 cells. The fusion protein was captured from the culture supernatant
on a HiTrap protein A HP column according to the manufacturer’s in-
structions (GE Healthcare). After washing with 20 mM sodium phos-
phate, the protein was eluted with 3 M MgCl2 before buffer exchange to
PBS. Binding of LASV to the alpha-DG–Fc fusion protein was done using
a protocol described previously, with the following modifications (20).
Briefly, microtiter plates were coated with 2 g/ml alpha-Dg–Fc fusion
protein overnight at 4°C. The coated plates were blocked for nonspecific
binding using 1% bovine serum albumin (BSA)–PBS. Equal volumes of
partially purified LASV were applied for 24 h at 4°C. For detection of
bound virus, a mixture of MAbs against GP1 (50 g/ml) and GP2 (1:10
dilution) was used in 1% BSA–PBS. Bound primary antibodies were de-
tected with peroxidase-conjugated secondary antibody against tetrameth-
ylbenzidine (TMB) substrate. The optical density at 450 nm was deter-
mined using a Synergy H1MD plate reader (BioTek, Winooski, VT, USA).
Endo-H and PNGase F treatment. In order to investigate the modifi-
cations of LASV glycoproteins, cell lysates were digested with Endo-H or
PNGase F (NEB, Ipswich, MA, USA) according to the manufacturer’s
instructions. The digested proteins were resolved by SDS-PAGE under
reducing conditions and were analyzed by Western blotting.
Error bars in all graphs represent standard deviations of the means,
with P values from Student’s t tests indicated (*, P  0.05; **, P  0.005).
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